StratDeck

Two stocks in Healthcare

Gerresheimer vs Sanofi: profit, growth, debt and price compared

Sanofi is stronger on 5 of 6 figures: profit margin, sales growth, debt, price for its expected profit and analysts' view. Gerresheimer is stronger on 1: price trend.

Figures as of 18 November 2026Yahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

Gerresheimer and Sanofi side by side
GerresheimerGXI.DESanofiSAN.PA
Net margin−17.5%Stronger: 8.2%
Revenue growth, past year−0.80%Stronger: +15.70%
Debt to equity236.7%Stronger: 27.1%
Forward P/E13.5×Stronger: 9.1×
Dividend yield—4.66%
AnalystsHold · 12Stronger: Buy · 23
From its 200-day averageStronger: +13.7%+12.2%

Share price over the past year

  • Gerresheimer+40.9%
  • Sanofi−0.1%

21 Nov 202518 Nov 2026

Gerresheimer or Sanofi: which is stronger?

  • SAN.PA

    Which is more profitable?

    Sanofi keeps more of each sale as profit: 8.2% against −17.5%.

  • SAN.PA

    Which is growing its sales faster?

    Sanofi is growing its sales faster: +15.70% over the past year, against −0.80%.

  • SAN.PA

    Which has borrowed less?

    Sanofi has borrowed less: its debt is 27.1% of what its shareholders own, against 236.7% for Gerresheimer.

  • SAN.PA

    Which costs less for the profit it is expected to make?

    Sanofi costs less for the profit it is expected to make: 9.1× its forward earnings, against 13.5×.

  • Which pays more in dividends?

    Sanofi pays 4.66% a year in dividends for what a share costs, where Gerresheimer pays none.

  • SAN.PA

    Which do analysts rate higher?

    Analysts are warmer on Sanofi: Buy, against Hold for Gerresheimer.

  • GXI.DE

    Which is in the stronger price trend?

    Gerresheimer's price is in the stronger trend: 13.7% above its 200-day average, against 12.2% above.

What each company does

GXI.DEGerresheimer

Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.

Reports results on 25 November 2026

SAN.PASanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.

Reports results on 28 January 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.